E M M Quigley1. 1. Department of Medicine, Alimentary Pharmbiotic Centre, University College Cork, Cork University Hospital, Clinical Sciences Building, Cork, Ireland. e.quigley@ucc.ie
Abstract
INTRODUCTION: Gastrointestinal symptoms such as heartburn, indigestion (or dyspepsia), bloating, distension, constipation, abdominal pain, abdominal discomfort and diarrhoea are extremely common worldwide. For some, such symptoms can prove to be chronic and disabling. METHODS: The recent literature on irritable bowel syndrome and, in particular, work emanating form this authors research group, was reviewed. RESULTS: These functional symptoms commonly occur in aggregations, referred to as functional gastrointestinal disorders (FGIDs). Some of the FGIDs and, most notably irritable bowel syndrome (IBS), have achieved a degree of scientific and clinical credibility as coherent entities. Several lines of evidence ranging from gut motility to the microbiota are under investigation in attempts to explain IBS or its symptomatology. CONCLUSION: Though biomarkers for IBS and other FGIDs have proven elusive, considerable progress has been made in understanding possible aetiological factors in IBS; progress which may well lead to better therapeutic strategies.
INTRODUCTION:Gastrointestinal symptoms such as heartburn, indigestion (or dyspepsia), bloating, distension, constipation, abdominal pain, abdominal discomfort and diarrhoea are extremely common worldwide. For some, such symptoms can prove to be chronic and disabling. METHODS: The recent literature on irritable bowel syndrome and, in particular, work emanating form this authors research group, was reviewed. RESULTS: These functional symptoms commonly occur in aggregations, referred to as functional gastrointestinal disorders (FGIDs). Some of the FGIDs and, most notably irritable bowel syndrome (IBS), have achieved a degree of scientific and clinical credibility as coherent entities. Several lines of evidence ranging from gut motility to the microbiota are under investigation in attempts to explain IBS or its symptomatology. CONCLUSION: Though biomarkers for IBS and other FGIDs have proven elusive, considerable progress has been made in understanding possible aetiological factors in IBS; progress which may well lead to better therapeutic strategies.
Authors: Vinton S Chadwick; Wangxue Chen; Dairu Shu; Barbara Paulus; Peter Bethwaite; Andy Tie; Ian Wilson Journal: Gastroenterology Date: 2002-06 Impact factor: 22.682
Authors: Owen J O'Connor; Sean E McSweeney; Sebastian McWilliams; Siobhan O'Neill; Fergus Shanahan; Eamonn M M Quigley; Michael M Maher Journal: Radiology Date: 2011-12-09 Impact factor: 11.105
Authors: Alan N Desmond; Sebastian McWilliams; Michael M Maher; Fergus Shanahan; Eamonn M Quigley Journal: Clin Gastroenterol Hepatol Date: 2011-11-12 Impact factor: 11.382
Authors: Paul Scully; Declan P McKernan; John Keohane; David Groeger; Fergus Shanahan; Timothy G Dinan; Eamonn M M Quigley Journal: Am J Gastroenterol Date: 2010-04-20 Impact factor: 10.864
Authors: Sarah S Mohamed; Nourtan F Abdeltawab; Walaa Wadie; Lamiaa A Ahmed; Ramy M Ammar; Sabine Rabini; Heba Abdel-Aziz; Mohamed T Khayyal Journal: BMC Complement Med Ther Date: 2021-06-08